Drug Trial Radar · NCT07297329
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
292
Planned (sponsor's estimate)
Start
Dec 29, 2025
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Sinocelltech Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate if the addition of SCTC21C to bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma not eligible for transplant will prolong progression-free survival (PFS) and/or improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.
Conditions
- Multiple Myeloma (MM)
Interventions
SCTC21CDrug
Pharmaceutical form: Solution for infusion; Route of administration: Subcutaneous
BortezomibDrug
Pharmaceutical form: Lyophilized powder for injection; Route of administration: Subcutaneous
LenalidomideDrug
Pharmaceutical form: Capsules; Route of administration: Oral
DexamethasoneDrug
Pharmaceutical form: Tablets, ampoules or vials for injection; Route of administration: Oral/Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: Up to approximately 84 months after the First Participant In (FPI)
- Minimal residual disease (MRD) negativity rate for participants with CRTime frame: Up to approximately 84 months after the FPI
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Chaoyang Hospital affiliated to Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.